Rivaroxaban - a Safe Therapeutic Option in Patients with Antiphospholipid Syndrome? Our Experience in 23 Cases

Overview

Journal Reumatologia

Publisher Termedia

Specialty Rheumatology

Date 2016 Aug 10

PMID 27504026

Citations 11

Authors

Ewa Haladyj

Marzena Olesinska

Affiliations

Soon will be listed here.

Abstract

In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutritional and therapeutic restrictions. The non-vitamin-K oral anticoagulants (NOAC) have a lot of advantages, but their efficacy and safety in APS have not been proven. We present 23 patients with APS treated with rivaroxaban in our department. Recurrence of thrombosis was observed only in 1 patient. No major or minor bleeding occurred. It proves the efficacy of treatment with rivaroxaban, but our observations require further prospective, randomized studies.

Citing Articles

Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials.

Adelhelm J, Christensen R, Balbi G, Voss A Lupus Sci Med. 2023; 10(2).

PMID: 37899090 PMC: 10619019. DOI: 10.1136/lupus-2023-001018.

Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.

Pastori D, Menichelli D, Cammisotto V, Pignatelli P Front Cardiovasc Med. 2021; 8:715878.

PMID: 34414220 PMC: 8368436. DOI: 10.3389/fcvm.2021.715878.

Monitoring of COVID-19-Associated Coagulopathy and Anticoagulation with Thromboelastometry.

Katz D, Maher P, Getrajdman C, Hamburger J, Zhao S, Madek J Transfus Med Hemother. 2021; 48(3):168-172.

PMID: 34177421 PMC: 8018202. DOI: 10.1159/000514486.

Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review.

Khodashahi M, Rezaieyazdi Z, Sahebari M Arch Rheumatol. 2020; 35(1):107-116.

PMID: 32637926 PMC: 7322308. DOI: 10.5606/ArchRheumatol.2020.7375.

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou M, Andreoli L, Limper M, Tincani A, Ward M RMD Open. 2019; 5(1):e000924.

PMID: 31168416 PMC: 6525610. DOI: 10.1136/rmdopen-2019-000924.

References

Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G . Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus. 2015; 25(3):301-6. DOI: 10.1177/0961203315611495. View

Win K, Rodgers G . New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014; 89(10):1017. DOI: 10.1002/ajh.23797. View

Cohen H, Dore C, Clawson S, Hunt B, Isenberg D, Khamashta M . Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015; 24(10):1087-94. PMC: 4527976. DOI: 10.1177/0961203315581207. View

Son M, Wypasek E, Celinska-Lowenhoff M, Undas A . The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res. 2015; 135(5):1035-6. DOI: 10.1016/j.thromres.2015.01.028. View

Della Valle P, Crippa L, Safa O, Tomassini L, Pattarini E, Grazia Sabbadini M . Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne (Paris). 1996; 147 Suppl 1:10-4. View

Chighizola C, Moia M, Meroni P . New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus. 2014; 23(12):1279-82. DOI: 10.1177/0961203314540968. View

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M . Antiphospholipid syndrome. Lancet. 2010; 376(9751):1498-509. DOI: 10.1016/S0140-6736(10)60709-X. View

Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L . Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015; 14(8):680-5. DOI: 10.1016/j.autrev.2015.03.007. View

Cohen H, Machin S . Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?. Lupus. 2010; 19(4):486-91. DOI: 10.1177/0961203310361355. View

10.

Schaefer J, McBane R, Black D, Williams L, Moder K, Wysokinski W . Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014; 112(5):947-50. DOI: 10.1160/TH14-03-0272. View

11.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

12.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

13.

Signorelli F, Nogueira F, Domingues V, Mariz H, Levy R . Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2015; 35(3):801-5. DOI: 10.1007/s10067-015-3030-y. View

14.

Peterson L, Willis R, Harris E, Branch W, Tebo A . Antibodies to Phosphatidylserine/Prothrombin Complex in Antiphospholipid Syndrome: Analytical and Clinical Perspectives. Adv Clin Chem. 2016; 73:1-28. DOI: 10.1016/bs.acc.2015.10.003. View

15.

Erkan D, Aguiar C, Andrade D, Cohen H, Cuadrado M, Danowski A . 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014; 13(6):685-96. DOI: 10.1016/j.autrev.2014.01.053. View

16.

Buller H, Prins M, Lensin A, Decousus H, Jacobson B, Minar E . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14):1287-97. DOI: 10.1056/NEJMoa1113572. View

17.

Sciascia S, Savino S, Breen K, Hunt B . Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015; 26(4):476-7. DOI: 10.1097/MBC.0000000000000247. View

18.

Agnelli G, Becattini C, Franco L . New oral anticoagulants for the treatment of venous thromboembolism. Best Pract Res Clin Haematol. 2013; 26(2):151-61. DOI: 10.1016/j.beha.2013.07.005. View